Improvement in global cognition seen for patients with Alzheimer disease\/MCI, but no effects seen for healthy individuals, other patient populations<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, June 30, 2023 (HealthDay News) — Intranasal insulin (INI) seems to have a beneficial effect on global cognition among patients with Alzheimer disease (AD)\/mild cognitive impairment (MCI), according to a review published online June 28 in PLOS ONE<\/em>.<\/p>\n Sally Wu, from the Center for Addiction and Mental Health at the University of Toronto, and colleagues conducted a systematic review and meta-analysis to examine the effects of INI on cognition in diverse patient populations and healthy individuals. Data were included from 29 studies with 1,726 healthy individuals and patients with AD\/MCI, mental health disorders, and metabolic disorders.<\/p>\n The researchers found that an improvement in global cognition was more likely among patients with AD\/MCI treated with INI (standardized mean difference, 0.22). No significant effects of INI were found for global cognition among healthy individuals and other patient populations.<\/p>\n “This systematic review and meta-analysis demonstrate that INI may be associated with pro-cognitive benefits, specifically for pooled global cognition. However, this effect is limited to patients with AD\/MCI,” the authors write. “As this is still a novel field of study, more research is required to understand the heterogeneity in treatment response of INI to extend the pro-cognitive benefits across different patient populations with the ultimate goal to improve their overall quality of life.”<\/p>\n Several authors disclosed ties to the biopharmaceutical industry.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n